News | December 07, 2024
Briefs: Venus Remedies and GPT Healthcare
Venus Remedies secures marketing authorization in Philippines
Venus Remedies secures marketing authorization in Philippines
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
The product will be marketed by Dr. Reddy's
New research labs and process development services to enable next generation therapeutics
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Modernization and supply chain diversity drive new growth
Subscribe To Our Newsletter & Stay Updated
